Research & Development

J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline

Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.

Sanofi and Owkin partner to develop next-generation biopharma AI agents

Sanofi has entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents.

Pfizer signs licence agreement with Chai for AI drug discovery

Pfizer and Chai Discovery have agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations.

Cellares and TScan to assess automated manufacturing of TSC-101 therapy

Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

Regeneron and CytomX extend cancer therapy partnership to $4bn deal

Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal’s total potential value rising to up to $4bn.

AbbVie receives EC approval for Aquipta to treat migraine

AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

BMS secures FDA acceptance for Camzyos sNDA

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos (mavacamten) to treat adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn

Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.

Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide

Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.